Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2024

Open Access 29-01-2024 | Cholangiocarcinoma | short review

Innovative therapeutic concepts for biliary tumors

Author: Dr. Angela Djanani

Published in: memo - Magazine of European Medical Oncology | Issue 1/2024

Login to get access

Summary

In recent years there have been significant changes in the treatment of bile duct carcinoma. Immunotherapy has been included in first-line treatment for about a year now (IO + cisplatin/gemcitabine). Cholangiocarcinomas are genetically very heterogeneous and several new targets have been identified in recent years. These play an important role, especially in second-line treatment. This review aims to highlight the key milestones of current treatment with a focus on targeted therapy options. Especially, current data on therapeutic options such as FGFR‑2, NTRK, IDH‑1, BRAF, HER‑2 are reported.
Literature
1.
Nakajima T, et al. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: Histologic classification and modes of spreading. Hum Pathol. 1988;19:1228–34.CrossRefPubMed
2.
Khan SA, et al. Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us? J Hepatol. 2012;56:848–85.CrossRefPubMed
3.
Lendvai G, Szekerczés T, Illyés I, et al. Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis. Pathol Oncol Res. 2020;26:3–15.CrossRefPubMed
4.
Carcinale V, et al. Intra-hepatic and extrahepatic cholangiocarcinoma.Nwe insight into epidemiology and risk factors. World J Gastrointest Oncol. 2010;2:407–16.CrossRef
5.
6.
Wang Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRefPubMed
7.
Lang H, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg. 2009;208(2):218–28.CrossRefPubMed
8.
Buettner S, et al. Survival after resection of multiple tumor foci of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2019;23(11):2239–46.CrossRefPubMedPubMedCentral
9.
Abdelrahim M, et al. Gemcitabine and cisplatin as neoadjuvant for cholangiocarcinoma patients prior to liver transplantation: a case-series. Curr Oncol. 2022;29:3585–94.CrossRefPubMedPubMedCentral
10.
Tan EK, et al. Liver transplantation for peri-hilar cholangiocarcinoma. J Gastrointest Surg. 2020;24:2679.CrossRefPubMed
11.
Edeline J, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. ASCO 2017 Gastrointestinal Cancer Symposium. J Clin Oncol. 2017;35(4S):225.CrossRef
12.
Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMed
13.
Oh DY, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8).
14.
Kelley RK, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–65.CrossRefPubMed
15.
16.
Abou-Alfa GK, et al. Ivosedenib in IDH1-mutatnt, chemotherapy refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807.CrossRefPubMedPubMedCentral
17.
Zhuet AX, et al. Final overall survival efficacy results of ivosidinib for patients with advanced cholangiocarcinoma with IDH1 mutation. JAMA Oncol. 2021;7(11):1669–77.CrossRef
18.
Arai Y, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34.CrossRefPubMed
19.
Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–84.CrossRefPubMedPubMedCentral
20.
21.
Galdy S, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and metaanalysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36:141–57.CrossRefPubMed
22.
Javle M, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multi-centre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290–300.CrossRefPubMed
23.
Weisser NE, Sanches M, EscobarCabrera E, et al. An antiHER2 biparatopic antibody that induces unique HER2 clustering and complementdependent cytotoxicity. Nat Commun. 2023;14:1394.ADSCrossRefPubMedPubMedCentral
24.
Harding JJ, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772–82.CrossRefPubMed
25.
Gieppert B, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27:1028–34.CrossRef
26.
Subbiah V, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–43.CrossRefPubMed
27.
Demols A, et al. NTRK gene fusions in biliary tract cancers. J Clin Oncol. 2020; 574.
28.
Hong DS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40.CrossRefPubMedPubMedCentral
Metadata
Title
Innovative therapeutic concepts for biliary tumors
Author
Dr. Angela Djanani
Publication date
29-01-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2024
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00956-4

Other articles of this Issue 1/2024

memo - Magazine of European Medical Oncology 1/2024 Go to the issue

editorial

Prostate cancer special—part 2

short review

Metastasis-directed therapy: new standard or too early to change paradigm?

short review

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review

short review

Management of oligometastatic prostate cancer

editorial

OeGHO annual meeting 2023—best of oncology

editorial

“Navigating the evolving landscape of cancer treatment: a triad of progress”
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits